<?xml version="1.0" encoding="UTF-8"?>
<p>In non-cirrhotic patients, the disease progression is stopped when SVR12 is achieved. Patients with cirrhosis may still develop decompensated cirrhosis (DCC) or hepatocellular carcinoma (HCC) despite reaching SVR12, but the likelihood of this is significantly lower compared to patients without SVR12 [
 <xref rid="B28-ijerph-17-00440" ref-type="bibr">28</xref>]. The transition probabilities are derived from available literature and shown in 
 <xref rid="ijerph-17-00440-t002" ref-type="table">Table 2</xref>. According to the recommendations of IQWIG, an annual discount rate of 3% was applied [
 <xref rid="B29-ijerph-17-00440" ref-type="bibr">29</xref>].
</p>
